Posted by ABMN Staff on May 6th, 2024
Wedbush restated their neutral rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report issued on Thursday, RTT News reports. They currently have a $21.00 price target on the medical equipment provider’s stock.
Several...
More of this article »